Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 462

1.

Evaluating Glomerular Filtration Rate Slope as a Surrogate End Point for ESKD in Clinical Trials: An Individual Participant Meta-Analysis of Observational Data.

Grams ME, Sang Y, Ballew SH, Matsushita K, Astor BC, Carrero JJ, Chang AR, Inker LA, Kenealy T, Kovesdy CP, Lee BJ, Levin A, Naimark D, Pena MJ, Schold JD, Shalev V, Wetzels JFM, Woodward M, Gansevoort RT, Levey AS, Coresh J.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010008. doi: 10.1681/ASN.2019010008. [Epub ahead of print]

PMID:
31292199
2.

Performance of GFR Slope as a Surrogate Endpoint for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.

Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA.

J Am Soc Nephrol. 2019 Jul 10. pii: ASN.2019010009. doi: 10.1681/ASN.2019010009. [Epub ahead of print]

PMID:
31292198
3.

Genetic Identification of Two Novel Loci Associated with Steroid-Sensitive Nephrotic Syndrome.

Dufek S, Cheshire C, Levine AP, Trompeter RS, Issler N, Stubbs M, Mozere M, Gupta S, Klootwijk E, Patel V, Hothi D, Waters A, Webb H, Tullus K, Jenkins L, Godinho L, Levtchenko E, Wetzels J, Knoers N, Teeninga N, Nauta J, Shalaby M, Eldesoky S, Kari JA, Thalgahagoda S, Ranawaka R, Abeyagunawardena A, Adeyemo A, Kristiansen M, Gbadegesin R, Webb NJ, Gale DP, Stanescu HC, Kleta R, Bockenhauer D.

J Am Soc Nephrol. 2019 Jul 1. pii: ASN.2018101054. doi: 10.1681/ASN.2018101054. [Epub ahead of print]

PMID:
31263063
4.

The authors reply.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M.

Kidney Int. 2019 Jul;96(1):249. doi: 10.1016/j.kint.2019.04.008. No abstract available.

PMID:
31229039
5.

Predicting kidney failure from longitudinal kidney function trajectory: A comparison of models.

van den Brand JAJG, Dijkstra TMH, Wetzels J, Stengel B, Metzger M, Blankestijn PJ, Lambers Heerspink HJ, Gansevoort RT.

PLoS One. 2019 May 9;14(5):e0216559. doi: 10.1371/journal.pone.0216559. eCollection 2019.

6.

The bias between different albumin assays may affect clinical decision-making.

van de Logt AE, Rijpma SR, Vink CH, Prudon-Rosmulder E, Wetzels JF, van Berkel M.

Kidney Int. 2019 Jun;95(6):1514-1517. doi: 10.1016/j.kint.2019.01.042. Epub 2019 Feb 27.

PMID:
31053386
7.

Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.

van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH; DIPAK-1 Investigators.

Gastroenterology. 2019 Apr 22. pii: S0016-5085(19)36711-3. doi: 10.1053/j.gastro.2019.04.018. [Epub ahead of print]

PMID:
31022403
8.

Placental passage of eculizumab and complement blockade in a newborn.

Duineveld C, Wijnsma KL, Volokhina EB, van den Heuvel LPB, van de Kar NCAJ, Wetzels JFM.

Kidney Int. 2019 Apr;95(4):996. doi: 10.1016/j.kint.2019.01.012. No abstract available.

PMID:
30904074
9.

Assessment of Plasma Resistivity as a Surrogate for Extracellular Fluid Resistivity: Analytical Performance and Impact of Fluid Composition.

Schotman JM, van Borren MMGJ, Wetzels JFM, Kloke HJ, Reichert LJM, de Boer H.

Ann Biomed Eng. 2019 Jun;47(6):1463-1469. doi: 10.1007/s10439-019-02246-9. Epub 2019 Mar 19.

PMID:
30891658
10.

Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy.

Zaghrini C, Seitz-Polski B, Justino J, Dolla G, Payré C, Jourde-Chiche N, Van de Logt AE, Booth C, Rigby E, Lonnbro-Widgren J, Nystrom J, Mariat C, Cui Z, Wetzels JFM, Ghiggeri G, Beck LH Jr, Ronco P, Debiec H, Lambeau G.

Kidney Int. 2019 Mar;95(3):666-679. doi: 10.1016/j.kint.2018.10.024.

PMID:
30784662
11.

Pharmacology, Pharmacokinetics and Pharmacodynamics of Eculizumab, and Possibilities for an Individualized Approach to Eculizumab.

Wijnsma KL, Ter Heine R, Moes DJAR, Langemeijer S, Schols SEM, Volokhina EB, van den Heuvel LP, Wetzels JFM, van de Kar NCAJ, Brüggemann RJ.

Clin Pharmacokinet. 2019 Jul;58(7):859-874. doi: 10.1007/s40262-019-00742-8. Review.

12.

NMR and MS urinary metabolic phenotyping in kidney diseases is fit-for-purpose in the presence of a protease inhibitor.

Boulangé CL, Rood IM, Posma JM, Lindon JC, Holmes E, Wetzels JFM, Deegens JKJ, Kaluarachchi MR.

Mol Omics. 2019 Feb 11;15(1):39-49. doi: 10.1039/c8mo00190a.

PMID:
30672550
13.

Management and treatment of glomerular diseases (part 1): conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Floege J, Barbour SJ, Cattran DC, Hogan JJ, Nachman PH, Tang SCW, Wetzels JFM, Cheung M, Wheeler DC, Winkelmayer WC, Rovin BH; Conference Participants.

Kidney Int. 2019 Feb;95(2):268-280. doi: 10.1016/j.kint.2018.10.018.

PMID:
30665568
14.

Correction to: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2019 Apr;34(4):741-742. doi: 10.1007/s00467-018-4186-x.

15.

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies.

Coresh J, Heerspink HJL, Sang Y, Matsushita K, Arnlov J, Astor BC, Black C, Brunskill NJ, Carrero JJ, Feldman HI, Fox CS, Inker LA, Ishani A, Ito S, Jassal S, Konta T, Polkinghorne K, Romundstad S, Solbu MD, Stempniewicz N, Stengel B, Tonelli M, Umesawa M, Waikar SS, Wen CP, Wetzels JFM, Woodward M, Grams ME, Kovesdy CP, Levey AS, Gansevoort RT; Chronic Kidney Disease Prognosis Consortium and Chronic Kidney Disease Epidemiology Collaboration.

Lancet Diabetes Endocrinol. 2019 Feb;7(2):115-127. doi: 10.1016/S2213-8587(18)30313-9. Epub 2019 Jan 8.

PMID:
30635225
16.

Masticatory function and related factors after oral oncological treatment: A 5-year prospective study.

de Groot RJ, Wetzels JW, Merkx MAW, Rosenberg AJWP, de Haan AFJ, van der Bilt A, Abbink JH, Speksnijder CM.

Head Neck. 2019 Jan;41(1):216-224. doi: 10.1002/hed.25445. Epub 2018 Dec 15.

17.

Antibodies Against M-Type Phospholipase Receptor and Prediction of Outcome in Membranous Nephropathy: We are Not There Yet.

Wetzels JFM.

Am J Nephrol. 2018;48(6):434-437. doi: 10.1159/000494661. Epub 2018 Nov 23. No abstract available.

18.

Progressive kidney failure in chronic myelomonocytic leukaemia: don't forget lysozyme damage.

Hillen JM, Raemaekers JM, Steenbergen EJ, Wetzels JFM, Verhave JC.

Neth J Med. 2018 Nov;76(9):407-410.

19.

Factors influencing neck and shoulder function after oral oncology treatment: a five-year prospective cohort study in 113 patients.

van Hinte G, Wetzels JGH, Merkx MAW, de Haan AFJ, Koole R, Speksnijder CM.

Support Care Cancer. 2019 Jul;27(7):2553-2560. doi: 10.1007/s00520-018-4534-1. Epub 2018 Nov 14.

20.

Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.

Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT; DIPAK-1 Investigators.

JAMA. 2018 Nov 20;320(19):2010-2019. doi: 10.1001/jama.2018.15870.

21.

Is there long-term value of pathology scoring in immunoglobulin A nephropathy? A validation study of the Oxford Classification for IgA Nephropathy (VALIGA) update.

Coppo R, D'Arrigo G, Tripepi G, Russo ML, Roberts ISD, Bellur S, Cattran D, Cook TH, Feehally J, Tesar V, Maixnerova D, Peruzzi L, Amore A, Lundberg S, Di Palma AM, Gesualdo L, Emma F, Rollino C, Praga M, Biancone L, Pani A, Feriozzi S, Polci R, Barratt J, Del Vecchio L, Locatelli F, Pierucci A, Caliskan Y, Perkowska-Ptasinska A, Durlik M, Moggia E, Ballarin JC, Wetzels JFM, Goumenos D, Papasotiriou M, Galesic K, Toric L, Papagianni A, Stangou M, Benozzi L, Cusinato S, Berg U, Topaloglu R, Maggio M, Ots-Rosenberg M, D'Amico M, Geddes C, Balafa O, Quaglia M, Cravero R, Lino Cirami C, Fellstrom B, Floege J, Egido J, Mallamaci F, Zoccali C.

Nephrol Dial Transplant. 2018 Nov 9. doi: 10.1093/ndt/gfy302. [Epub ahead of print]

PMID:
30418652
22.

Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use.

Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ.

Pediatr Nephrol. 2018 Nov 6. doi: 10.1007/s00467-018-4091-3. [Epub ahead of print] Review. Erratum in: Pediatr Nephrol. 2019 Jan 15;:.

PMID:
30402748
23.

The Use of N-of-1 Trials to Individualize Treatment in Patients With Renal Magnesium Wasting.

Bech AP, Wetzels JFM, Groenewoud H, Nijenhuis T.

Am J Kidney Dis. 2019 Feb;73(2):288-290. doi: 10.1053/j.ajkd.2018.08.010. Epub 2018 Oct 11. No abstract available.

PMID:
30318133
24.

Urine Acidification After Ammonium Chloride.

Bech AP, Nijenhuis T, Wetzels JFM.

Am J Kidney Dis. 2018 Dec;72(6):909-911. doi: 10.1053/j.ajkd.2018.07.018. Epub 2018 Oct 5. No abstract available.

PMID:
30297083
25.

The authors reply.

van de Logt AE, Dahan K, Ronco P, Wetzels J.

Kidney Int. 2018 Oct;94(4):830. doi: 10.1016/j.kint.2018.06.018. No abstract available.

PMID:
30243321
26.

Nephrotic Syndrome With Mutations in NPHS2: The Role of R229Q and Implications for Genetic Counseling.

Rood IM, Deegens JKJ, Lugtenberg D, Bongers EMHF, Wetzels JFM.

Am J Kidney Dis. 2019 Mar;73(3):400-403. doi: 10.1053/j.ajkd.2018.06.034. Epub 2018 Sep 18.

PMID:
30241959
27.

Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy.

Duineveld C, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2018 Dec;72(6):906. doi: 10.1053/j.ajkd.2018.07.013. Epub 2018 Sep 17. No abstract available.

PMID:
30236630
28.

Yield of diagnostic tests in unexplained renal hypophosphatemia: a case series.

Bech AP, Hoorn EJ, Zietse R, Wetzels JFM, Nijenhuis T.

BMC Nephrol. 2018 Sep 4;19(1):220. doi: 10.1186/s12882-018-1017-z.

29.

What Patients with Mild-to-Moderate Kidney Disease Know, Think, and Feel about Their Disease: An In-Depth Interview Study.

van Dipten C, de Grauw WJC, Wetzels JFM, Assendelft WJJ, Scherpbier-de Haan ND, Dees MK.

J Am Board Fam Med. 2018 Jul-Aug;31(4):570-577. doi: 10.3122/jabfm.2018.04.170459.

30.

The Calcium-Dependent Protease Calpain-1 Links TRPC6 Activity to Podocyte Injury.

Verheijden KAT, Sonneveld R, Bakker-van Bebber M, Wetzels JFM, van der Vlag J, Nijenhuis T.

J Am Soc Nephrol. 2018 Aug;29(8):2099-2109. doi: 10.1681/ASN.2016111248. Epub 2018 Jun 28.

PMID:
29954830
31.

General practitioners' perspectives on management of early-stage chronic kidney disease: a focus group study.

van Dipten C, van Berkel S, de Grauw WJC, Scherpbier-de Haan ND, Brongers B, van Spaendonck K, Wetzels JFM, Assendelft WJJ, Dees MK.

BMC Fam Pract. 2018 Jun 6;19(1):81. doi: 10.1186/s12875-018-0736-3.

32.

Effects of sildenafil, metformin, and simvastatin on ADH-independent urine concentration in healthy volunteers.

Bech AP, Wetzels JFM, Nijenhuis T.

Physiol Rep. 2018 Apr;6(7):e13665. doi: 10.14814/phy2.13665.

33.

Immunological remission in PLA2R-antibody-associated membranous nephropathy: cyclophosphamide versus rituximab.

van de Logt AE, Dahan K, Rousseau A, van der Molen R, Debiec H, Ronco P, Wetzels J.

Kidney Int. 2018 Apr;93(4):1016-1017. doi: 10.1016/j.kint.2017.12.019. No abstract available.

PMID:
29571438
34.

Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice.

Rops ALWMM, Jansen E, van der Schaaf A, Pieterse E, Rother N, Hofstra J, Dijkman HBPM, van de Logt AE, Wetzels J, van der Vlag J, van Spriel AB.

Kidney Int. 2018 Jun;93(6):1356-1366. doi: 10.1016/j.kint.2018.01.005. Epub 2018 Mar 16.

PMID:
29551516
35.

Neuropeptide Y and chronic kidney disease progression: a cohort study.

Zoccali C, D'Arrigo G, Leonardis D, Pizzini P, Postorino M, Tripepi G, Mallamaci F, van den Brand J, van Zuilen A, Wetzels J, Bots ML, Blankestijn P.

Nephrol Dial Transplant. 2018 Oct 1;33(10):1805-1812. doi: 10.1093/ndt/gfx351.

PMID:
29370406
36.

CD44 is required for the pathogenesis of experimental crescentic glomerulonephritis and collapsing focal segmental glomerulosclerosis.

Eymael J, Sharma S, Loeven MA, Wetzels JF, Mooren F, Florquin S, Deegens JK, Willemsen BK, Sharma V, van Kuppevelt TH, Bakker MA, Ostendorf T, Moeller MJ, Dijkman HB, Smeets B, van der Vlag J.

Kidney Int. 2018 Mar;93(3):626-642. doi: 10.1016/j.kint.2017.09.020. Epub 2017 Dec 21.

PMID:
29276101
37.

Reference values of renal tubular function tests are dependent on age and kidney function.

Bech AP, Wetzels JFM, Nijenhuis T.

Physiol Rep. 2017 Dec;5(23). doi: 10.14814/phy2.13542.

38.

Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome.

Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar NCAJ, Wetzels JFM.

Nephrol Dial Transplant. 2018 Apr 1;33(4):635-645. doi: 10.1093/ndt/gfx196.

PMID:
29106598
39.

Differential diagnosis of thrombotic microangiopathy in nephrology.

Sakari Jokiranta T, Viklicky O, Al Shorafa S, Coppo R, Gasteyger C, Macia M, Pankratenko T, Shenoy M, Soylemezoglu O, Tsimaratos M, Wetzels J, Haller H.

BMC Nephrol. 2017 Oct 28;18(1):324. doi: 10.1186/s12882-017-0727-y.

40.

Renal physiology: Prostaglandins in thiazide-induced hyponatraemia: do they hold water?

Hoorn EJ, Wetzels JFM.

Nat Rev Nephrol. 2017 Nov;13(11):665-666. doi: 10.1038/nrneph.2017.133. Epub 2017 Sep 25. No abstract available.

PMID:
28944774
41.

The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.

D'Agnolo HMA, Casteleijn NF, Gevers TJG, de Fijter H, van Gastel MDA, Messchendorp AL, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JFM, Zietse R, Gansevoort RT, Drenth JPH.

Am J Nephrol. 2017;46(3):239-248. doi: 10.1159/000479436. Epub 2017 Sep 8.

PMID:
28881341
42.

Living Donor Kidney Transplantation in Atypical Hemolytic Uremic Syndrome: A Case Series.

Duineveld C, Verhave JC, Berger SP, van de Kar NCAJ, Wetzels JFM.

Am J Kidney Dis. 2017 Dec;70(6):770-777. doi: 10.1053/j.ajkd.2017.06.024. Epub 2017 Aug 16.

PMID:
28821363
43.

A Novel Hypokalemic-Alkalotic Salt-Losing Tubulopathy in Patients with CLDN10 Mutations.

Bongers EMHF, Shelton LM, Milatz S, Verkaart S, Bech AP, Schoots J, Cornelissen EAM, Bleich M, Hoenderop JGJ, Wetzels JFM, Lugtenberg D, Nijenhuis T.

J Am Soc Nephrol. 2017 Oct;28(10):3118-3128. doi: 10.1681/ASN.2016080881. Epub 2017 Jul 3.

44.

Disposition and clinical implications of protein-bound uremic toxins.

Jansen J, Jankowski J, Gajjala PR, Wetzels JFM, Masereeuw R.

Clin Sci (Lond). 2017 Jun 30;131(14):1631-1647. doi: 10.1042/CS20160191. Print 2017 Jul 15. Review.

PMID:
28667064
45.

Use of the Furosemide Fludrocortisone Test to Clinically Assess Distal Tubular Acidification.

Bech AP, Wetzels JFM, Nijenhuis T.

Am J Kidney Dis. 2017 Oct;70(4):589-591. doi: 10.1053/j.ajkd.2017.05.009. Epub 2017 Jun 17. No abstract available.

PMID:
28634085
46.

Lithium-induced NDI: acetazolamide reduces polyuria but does not improve urine concentrating ability.

de Groot T, Doornebal J, Christensen BM, Cockx S, Sinke AP, Baumgarten R, Bedford JJ, Walker RJ, Wetzels JFM, Deen PMT.

Am J Physiol Renal Physiol. 2017 Sep 1;313(3):F669-F676. doi: 10.1152/ajprenal.00147.2017. Epub 2017 Jun 14.

47.

Urinary Excretion of α1-Microglobulin Does Not Predict Graft Loss in Stable Kidney Transplant Recipients.

Bech AP, Hoogendijk JM, Wetzels JF.

Am J Kidney Dis. 2017 Jul;70(1):151. doi: 10.1053/j.ajkd.2017.02.377. Epub 2017 May 10. No abstract available.

PMID:
28501240
48.

Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy.

van den Brand JAJG, Ruggenenti P, Chianca A, Hofstra JM, Perna A, Ruggiero B, Wetzels JFM, Remuzzi G.

J Am Soc Nephrol. 2017 Sep;28(9):2729-2737. doi: 10.1681/ASN.2016091022. Epub 2017 May 9.

49.

Clinical Relevance of Differences in Glomerular Filtration Rate Estimations in Frail Older People by Creatinine- vs. Cystatin C-Based Formulae.

Jacobs A, Benraad C, Wetzels J, Rikkert MO, Kramers C.

Drugs Aging. 2017 Jun;34(6):445-452. doi: 10.1007/s40266-017-0460-z.

PMID:
28405944
50.

Cost-effectiveness of eculizumab treatment after kidney transplantation in patients with atypical haemolytic uraemic syndrome.

van den Brand JA, Verhave JC, Adang EM, Wetzels JF.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i115-i122. doi: 10.1093/ndt/gfw353.

PMID:
28391343

Supplemental Content

Loading ...
Support Center